Advertisement


Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone

ASCO20 Virtual Scientific Program

Advertisement

Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial, which showed bortezomib, lenalidomide, and dexamethasone should remain the standard of care in patients with newly diagnosed standard- or intermediate-risk multiple myeloma, for whom early autologous stem cell transplant is not intended (Abstract LBA3).



Related Videos

Lung Cancer
COVID-19

Leora Horn, MD, on Thoracic Cancer and COVID-19: How Type of Cancer Therapy May Affect Survival

Leora Horn, MD, of Vanderbilt University, discusses the results of the TERAVOLT study, launched by the Thoracic Cancers International COVID-19 Collaboration. It examined the impact of specific chemotherapy and immunotherapy regimens on hospitalization and risk of death in patients with thoracic malignancies who are also infected with COVID-19 (Abstract LBA111).

Lymphoma
Immunotherapy

Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy

Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve only a PET/CT-positive partial remission, is appropriate in the era of CAR T-cell therapy (Abstract 8000).

Gynecologic Cancers

Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease

Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).

Prostate Cancer

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

Lymphoma
Immunotherapy

Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment

Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).

Advertisement

Advertisement




Advertisement